"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"

NCT03538717

Last updated date
Study Location
Hospital Universitario Rey Juan carlos
Mostoles, Madrid, 28933, Spain
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Carcinoma, Renal Cell
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Age ≥ 18 years

- Patients with advanced or metastatic renal cell carcinoma, histologically confirmed, with at least one radiological response assessment

- Patients who had received Axitinib treatment in second or further line with a PFS ≥9 months or DP (disease progression) at the first tumor assessment.

- For the patients alive at the moment of the inclusion, patients must have a signed informed consent document

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Axitinib received out of the approved indication Patients who do not meet any of the
inclusion criteria

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Carcinoma, Renal Cell"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"
NCT03538717
  1. Mostoles, Madrid
  2. Orense,
  3. Hospitalet de Llobregat, Barcelona
  4. Sabadell, Barcelona
  5. Tarragona, Barcelona
  6. Terrassa, Barcelona
  7. Alcazar de San Juan, Ciudad REAL
  8. Alcalá de Henares, Madrid
  9. Alcorcón, Madrid
  10. Leganés, Madrid
  11. Parla, Madrid
  12. San Sebatián De Los Reyes, Madrid
  13. Palma de Mallorca, Mallorca
  14. Pamplona, Navarra
  15. La Cuesta, Santa Cruz De Tenerife, Tenerife
  16. Santa Cruz de Tenerife, Tenerife
  17. Talavera de la Reina, Toledo
  18. Barcelona,
  19. Barcelona,
  20. Barcelona,
  21. Barcelona,
  22. Ciudad Real,
  23. Córdoba,
  24. Jaén,
  25. León,
  26. Lugo,
  27. Madrid,
  28. Madrid,
  29. Madrid,
  30. Madrid,
  31. Madrid,
  32. Oviedo,
  33. Santiago de Compostela,
  34. Toledo,
  35. Valencia,
  36. Valencia,
  37. Valencia,
  38. Vigo,
  39. Zaragoza,
  40. Zaragoza,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Carcinoma, Renal CellStudy of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
NCT04033991
  1. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Carcinoma, Renal CellSU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
NCT00083889
  1. Jonesboro, Arkansas
  2. La Jolla, California
  3. La Jolla, California
  4. Los Angeles, California
  5. San Diego, California
  6. San Francisco, California
  7. Aurora, Colorado
  8. New Haven, Connecticut
  9. New Haven, Connecticut
  10. New Haven, Connecticut
  11. Miami, Florida
  12. Miami, Florida
  13. Tampa, Florida
  14. Chicago, Illinois
  15. Maywood, Illinois
  16. Kansas City, Kansas
  17. Overland Park, Kansas
  18. Louisville, Kentucky
  19. Covington, Louisiana
  20. Metairie, Louisiana
  21. Metairie, Louisiana
  22. Baltimore, Maryland
  23. Boston, Massachusetts
  24. Boston, Massachusetts
  25. Detoit, Michigan
  26. Detroit, Michigan
  27. Farmington Hills, Michigan
  28. Minneapolis, Minnesota
  29. Columbus, Mississippi
  30. Corinth, Mississippi
  31. Jackson, Mississippi
  32. Jackson, Mississippi
  33. Southaven, Mississippi
  34. Tupelo, Mississippi
  35. Kansas City, Missouri
  36. Omaha, Nebraska
  37. Lebanon, New Hampshire
  38. Bronx, New York
  39. New York, New York
  40. New York, New York
  41. Cleveland, Ohio
  42. Cleveland, Ohio
  43. Tulsa, Oklahoma
  44. Tulsa, Oklahoma
  45. Tulsa, Oklahoma
  46. Portland, Oregon
  47. Portland, Oregon
  48. Philadelphia, Pennsylvania
  49. Memphis, Tennessee
  50. Memphis, Tennessee
  51. Nashville, Tennessee
  52. Dallas, Texas
  53. Houston, Texas
  54. Tyler, Texas
  55. Salt Lake City, Utah
  56. Seattle, Washington
  57. Seattle, Washington
  58. Madison, Wisconsin
  59. Lismore, New South Wales
  60. St. Leonards, New South Wales
  61. South Brisbane, Queensland
  62. Woodville South, South Australia
  63. East Melbourne, Victoria
  64. Perth, Western Australia
  65. Victoria,
  66. Rio de Janeiro, RJ
  67. Porto Alegre, RS
  68. Porto Alegre, RS
  69. Calgary, Alberta
  70. Edmonton, Alberta
  71. Kelowna, British Columbia
  72. Vancouver, British Columbia
  73. Victoria, British Columbia
  74. London, Ontario
  75. Toronto, Ontario
  76. Toronto, Ontario
  77. Montreal, Quebec
  78. Quebec,
  79. Quebec,
  80. Paris, Cedex 15
  81. Lyon,
  82. Paris Cedex 13,
  83. Rennes,
  84. Saint Herblain,
  85. Vandoeuvre Les Nancy,
  86. Aachen,
  87. Essen,
  88. Hannover,
  89. Ulm,
  90. Ulm,
  91. Modena,
  92. Napoli,
  93. Pavia,
  94. Roma,
  95. Roma,
  96. Roma,
  97. Moczowego, Warszawa
  98. Gdansk,
  99. Krakow,
  100. Lodz,
  101. Lublin,
  102. Poznan,
  103. Warszawa,
  104. Wroclaw,
  105. Wroclaw,
  106. Obninsk, Kaluga Region
  107. Chelyabinsk,
  108. Moscow,
  109. Moscow,
  110. Moscow,
  111. Saint-Petersburg,
  112. St. Petersburg,
  113. Tomsk,
  114. Hospitalet de Llobregat, Barcelona
  115. Pamplona, Navarra
  116. Madrid,
  117. Madrid,
  118. Sevilla,
  119. Whitchurch, Cardiff
  120. Manchester, Lancashire
  121. Northwood, Middlesex
  122. London,
  123. London,
  124. Sutton Surrey,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title "Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"
Official Title ANÁLISIS RETROSPECTIVO DE FACTORES CLÍNICOS ASOCIADOS A UN MAYOR BENEFICIO CON AXITINIB EN CÁNCER RENAL METASTÁSICO. (ESTUDIO AXILONG)
Brief Summary Retrospective study to collect data from Patients with advanced/metastatic renal cell carcinoma previously treated with Axitinib under standard clinical practice, to describe the clinical profile of the patients with a long response to Axitinib and to try to identify clinical factors which could be related with the long response to Axitinib, through the comparison between long responder patients and a group of refractory patients
Detailed Description

To describe the clinical profile of patients with a long response to Axitinib and to identify clinical factors which could be related with the long response to Axitinib, through the comparison between long responder patients and a group of refractory patients.

For this study are defined as "long responder", those patients who has a Progression Free Survival (PFS) of at least 9 months since the initiation of Axitinib treatment, and "refractory patients" those who have Progression Disease (PD) in the first response assessment since the initiation of Axitinib treatment (estimated PFS ?3 months]

Secondary Objectives

  • To describe the efficacy of Axitinib treatment in the long responders group, and in relation with the treatment received before Axitinib, in terms of PFS, ORR, CB, OS, TTP ...
  • To describe the tolerability and drug management of Axitinib in this population.
  • To describe treatment received after Axitinib in this population.

Study procedures:

For the recruitment, the Investigator should review the inclusion / exclusion criteria. In case of patients alive at the moment of the inclusion, the investigator will require them to sign the IC.

With the data available in the medical records, the information requested will be recorded in the electronic data collection tool.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population

- Age ? 18 years

  • Patients with advanced or metastatic renal cell carcinoma, histologically confirmed, with at least one radiological response assessment
  • Patients who had received Axitinib treatment in second or further line with a PFS ?9 months or DP (disease progression) at the first tumor assessment.
  • For the patients alive at the moment of the inclusion, patients must have a signed informed consent document
Condition Carcinoma, Renal Cell
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: February 27, 2020)
157
Original Estimated Enrollment
 (submitted: May 24, 2018)
60
Actual Study Completion Date March 1, 2019
Actual Primary Completion Date March 1, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Age ? 18 years

    • Patients with advanced or metastatic renal cell carcinoma, histologically confirmed, with at least one radiological response assessment
    • Patients who had received Axitinib treatment in second or further line with a PFS ?9 months or DP (disease progression) at the first tumor assessment.
    • For the patients alive at the moment of the inclusion, patients must have a signed informed consent document

Exclusion Criteria:

  • Axitinib received out of the approved indication Patients who do not meet any of the inclusion criteria
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Spain
Removed Location Countries  
 
Administrative Information
NCT Number NCT03538717
Other Study ID Numbers A4061089
AXILONG ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date February 2020